Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed endocrinologists indicate that a therapy's effect on glycosylated hemoglobin A1c (HbA1c) is the attribute that most influences their prescribing decisions in type 2 diabetes. Clinical data and the opinions of interviewed thought leaders indicate that Alkermes/Amylin/Eli Lilly's Byetta LAR and Novo Nordisk's Victoza have advantages in this attribute over Takeda's Actos, the sales-leading agent in the market.

The new report entitled Type 2 Diabetes: Endocrinologists' Satisfaction with Inexpensive Metformin Sets High Hurdles for Emerging Agents finds that a drug that is substantially more effective than metformin (Bristol-Myers Squibb/Merck Serono's Glucophage, generics) at reducing HbA1c and offers improvements in terms of convenience would earn a 33 percent patient share in type 2 diabetes in the United States and a 30 percent patient share in Europe, according to surveyed U.S. and European endocrinologists.

In 2008, Decision Resources' proprietary clinical gold standard for type 2 diabetes was Byetta (exenatide), owing to its efficacy and its propensity to cause weight loss. Based on available data and expert opinion, Byetta LAR will earn gold-standard status for type 2 diabetes in 2012, following its approval for the indication in that year.

"Byetta LAR has competitive advantages in terms of delivery compared with the current gold standard," said Decision Resources Analyst Caroline Gates. "Furthermore, in a 30-week, randomized, open-label clinical trial involving nearly 300 type 2 diabetics, patients treated with Byetta LAR demonstrated statistically significant improvements in glycemic control over patients receiving exenatide."

About the Report

Type 2 Diabetes: Endocrinologists' Satisfaction with Inexpensive Metformin Sets High Hurdles for Emerging Agents is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources                           Decision Resources, Inc.   Christopher Comfort                          Elizabeth Marshall   781-296-2597                                 781-296-2563   ccomfort@dresources.com                      emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com, or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients

View Now